对于耐火性克罗恩病的三重生物疗法
Sophie Vieujean1,2, Laurent Peyrin-Biroulet2
1Hepato-Gastroenterology and Digestive Oncology, University Hospital CHU of Liège, Liège, Belgium.
Journal of Crohn's & colitis
|April 19, 2025
概括
对于耐火性克罗恩病 (CD) 的三重生物疗法在复杂的病例中没有益处,同时有结性脊柱炎. 这种实验方法需要进一步研究在特定患者的疗效和安全性.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 克罗恩病 (CD) 的管理面临着耐火病例的挑战.
- 双重向治疗 (DTT) 显示出有希望的结果,但三重生物疗法很少被报道.
- 免疫介导疾病的重叠使治疗决策复杂化.
研究的目的:
- 报告一个罕见的三重生物疗法的病例,该病例发生在一个耐火性克罗恩病和结性脊柱炎的患者身上.
- 评估特定三重生物组合的疗效和耐受性.
- 要突出管理耐火性炎症性肠病与并发症的复杂性.
主要方法:
- 一个30岁的男性患有耐火性CD和结性脊柱炎的病例报告.
- 患者先前接受过多种疗法,包括抗TNF药物,维多利祖马布,乌斯特基努马布和乌帕达西提尼布.
- 开始了10个月的三重生物疗法,包括certollizumab pegol,ustekinumab 和 vedolizumab.
主要成果:
- 三重生物疗法被很好地容忍.
- 化脊柱炎仍然处于缓解状态.
- 在克罗恩病活动中没有观察到临床改善.
结论:
- 三重生物疗法是耐火性IBD与并发症的实验性治疗.
- 三重治疗的有效性仍然不确定,需要谨慎的方法.
- 需要进一步的研究来确定合适的患者和三重治疗的最佳组合.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
241
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
241
Drugs for Treatment of Ulcerative Colitis in IBD
104
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
104


